Statement on the benefit assessment of trastuzumab deruxtecan (adenocarcinoma of the stomach or gastroesophageal junction, HER2-positive) of May 23, 2023

被引：0
|
作者：
不详
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2023年 / 61卷 / 07期
关键词：
D O I：
10.1055/a-2110-6846
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：938 / 942
页数：5
相关论文
共 50 条
  • [1] Phase 2 study of trastuzumab deruxtecan as neoadjuvant treatment for HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003).
    Takahari, Daisuke
    Kawazoe, Akihito
    Machida, Nozomu
    Minashi, Keiko
    Yamagata, Yukinori
    Hara, Hiroki
    Omori, Takeshi
    Yamamoto, Manabu
    Yasui, Hisateru
    Nakayama, Izuma
    Yamada, Takanobu
    Kano, Masayuki
    Yoshikawa, Takaki
    Wakabayashi, Masashi
    Komura, Yu
    Sato, Akihiro
    Kuwata, Takeshi
    Kojima, Motohiro
    Kinoshita, Takahiro
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 309 - 309
  • [2] Phase 2 study of trastuzumab deruxtecan in the neoadjuvant treatment for patients with HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003)
    Takahari, Daisuke
    Kawazoe, Akihito
    Machida, Nozomu
    Minashi, Keiko
    Yamagata, Yukinori
    Hara, Hiroki
    Wakabayashi, Masashi
    Komura, Yu
    Sato, Akihiro
    Kuwata, Takeshi
    Kojima, Motohiro
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer
    Jubashi, Amane
    Nakayama, Izuma
    Koganemaru, Shigehiro
    Sakamoto, Naoya
    Oda, Shioto
    Matsubara, Yuki
    Miyashita, Yu
    Sato, Seiya
    Ushiyama, Shinpei
    Kobayashi, Akinori
    Okazaki, Ukyo
    Okemoto, Dai
    Yamamoto, Kazumasa
    Mishima, Saori
    Kotani, Daisuke
    Kawazoe, Akihito
    Hashimoto, Tadayoshi
    Nakamura, Yoshiaki
    Kuboki, Yasutoshi
    Bando, Hideaki
    Kojima, Takashi
    Yoshino, Takayuki
    Miyaaki, Hisamitsu
    Nakao, Kazuhiko
    Shitara, Kohei
    GASTRIC CANCER, 2025, 28 (01) : 63 - 73
  • [4] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
  • [5] A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
    Fuchs, C.
    Shahidi, J.
    Mathew, L.
    Qin, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S150 - S150
  • [6] Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer
    Mishima, Saori
    Shitara, Kohei
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 825 - 830
  • [7] Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
    Dhanushkodi, Manikandan
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 556 - 558
  • [8] Trastuzumab-Deruxtecan in the Therapy of HER2-positive Breast Cancer
    Schmale, Ine
    BREAST CARE, 2021, 16 (03)
  • [9] Trastuzumab Deruxtecan in cerebral metastatic HER2-positive Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (04) : 354 - 354
  • [10] Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
    Perez, Jose
    Garrigos, Laia
    Gion, Maria
    Janne, Pasi A.
    Shitara, Kohei
    Siena, Salvatore
    Cortes, Javier
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 811 - 824
12345